论文部分内容阅读
急性髓系白血病(AML)是一组造血干祖细胞的恶性克隆性疾病。随着新药的研发、骨髓移植的广泛运用以及支持治疗水平的提高,近年来AML的完全缓解(CR)率和生存期有了明显提高,但仍有20%~35%的成年人和3%~17%的儿童AML属于难治〔1〕。对于难治性AML的处理仍然是血液科医生的一大难题。我们于2012-01-2013-01应用地西他滨联合AAEG方案治疗难治性AML
Acute myeloid leukemia (AML) is a group of malignant clonal diseases that are hematopoietic stem and progenitor cells. With the development of new drugs, the extensive use of bone marrow transplantation and the increase of supportive treatment, the complete remission (CR) rate and survival of AML have been significantly improved in recent years. However, 20% to 35% of adults and 3% ~ 17% of children with AML are refractory 〔1〕. Treatment of refractory AML remains a major problem for hematologists. We treated decitabine AML with decitabine plus AAEG regimen from January 2012 to January 2013